<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00760877</url>
  </required_header>
  <id_info>
    <org_study_id>CAMN107A2405</org_study_id>
    <secondary_id>2009-012616-40</secondary_id>
    <nct_id>NCT00760877</nct_id>
  </id_info>
  <brief_title>Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR)</brief_title>
  <official_title>An Open Label, Randomized Study of Nilotinib vs. Standard Imatinib (400/600 mg QD) Comparing the Kinetics of Complete Molecular Response for CML-CP Patients With Evidence of Persistent Leukemia by RQ-PCR.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of this study was to determine the rate of confirmed best cumulative
      complete molecular response (CMR) within the first year of study therapy with imatinib or
      nilotinib. The study also explored the impact and significance of the achieved CMR on patient
      outcomes (progression free survival (PFS), event free survival (EFS) and overall survival
      (OS), characterized the kinetics of CMR achieved in both treatment arms and after the
      cross-over.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Confirmed Best Cumulative Complete Molecular Response (CMR)</measure>
    <time_frame>12 months</time_frame>
    <description>The rate of confirmed best cumulative CMR was defined as the number of participants who had confirmed CMR during the first 12 months of treatment after the randomization date. Participants who achieved confirmed best cumulative CMR during the first 12 months were considered responders. Participants who dropped out early or who did not provide sufficient data for any reason were considered to be non-responders. The definition of CMR is undetectable BCR-ABL (fusion gene formed between bcr gene from chromosome 22 and abl gene from chromosome 9) where BCR-ABL ratio in % international scale (IS) ≤ 0.00001 by real-time quantitative polymerase chain reaction (RQ-PCR) where there was no detectable BCR-ABL and 1) the test had a sensitivity of at least 4.5 logs below the standardized baseline; 2) RQ-PCR negativity was confirmed on the next RQ-PCR sample (usually 3 months later); and 3) the date of confirmed CMR was the date of the first of two negative results with sensitivity &gt;4.5 logs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Confirmed Best Cumulative CMR</measure>
    <time_frame>24 months, 36 month, 48 months</time_frame>
    <description>The rate of confirmed best cumulative CMR was defined as the number of participants who had confirmed CMR during the 24, 36 and 48 months post treatment after the randomization date. Participants who achieved confirmed best cumulative CMR during the first 12 months were considered responders. Participants who dropped out early or who did not provide sufficient data for any reason were considered to be non-responders. The definition of CMR is undetectable BCR-ABL (fusion gene formed between bcr gene from chromosome 22 and abl gene from chromosome 9) where BCR-ABL ratio in % international scale (IS) ≤ 0.00001 by RQ-PCR where there was no detectable BCR-ABL and 1) the test had a sensitivity of at least 4.5 logs below the standardized baseline; 2) RQ-PCR negativity was confirmed on the next RQ-PCR sample (usually 3 months later); and 3) the date of confirmed CMR was the date of the first of two negative results with sensitivity &gt;4.5 logs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Cross-over Participants With CMR</measure>
    <time_frame>24 months, 36 months, 48 months</time_frame>
    <description>The definition of CMR is undetectable BCR-ABL (fusion gene formed between bcr gene from chromosome 22 and abl gene from chromosome 9) where BCR-ABL ratio in % international scale (IS) ≤ 0.00001 by RQ-PCR where there was no detectable BCR-ABL and 1) the test had a sensitivity of at least 4.5 logs below the standardized baseline; 2) RQ-PCR negativity was confirmed on the next RQ-PCR sample (usually 3 months later); and 3) the date of confirmed CMR was the date of the first of two negative results with sensitivity &gt;4.5 logs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>48 months</time_frame>
    <description>PFS was defined as the time from the date of randomization to the date of the earliest documented progression-defining event as follows: transformation to blast crisis or accelerated phase disease, or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free Survival</measure>
    <time_frame>48 months</time_frame>
    <description>Event-free survival was defined as the time from the date of randomization to the date of first occurrence of any of the following events on study treatment: loss of complete hematological response, confirmed loss of complete cytogenetic response (CCyR), confirmed loss of major molecular response (MMR), death from any cause during treatment, progression to the accelerated phase or blast crisis of chronic myelogenous leukemia (CML) per European Leukemia Network (ELN) criteria, whichever was earliest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>48 months</time_frame>
    <description>Overall survival was defined as the time from the date of randomization to the date of death due to any cause at any time during the study, including the follow-up period after discontinuation of treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">207</enrollment>
  <condition>CHRONIC MYELOGENOUS LEUKEMIA</condition>
  <arm_group>
    <arm_group_label>Nilotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received Nilotinib 400 mg orally twice daily (bid) for 48 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Imatinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received Imatinib 400 mg or 600 mg once daily (qd) (based on the participant's dose prior to randomization) for 48 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nilotinib</intervention_name>
    <description>Supplied in 200 mg capsules</description>
    <arm_group_label>Nilotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib</intervention_name>
    <description>Supplied in 100 mg and 400 mg capsules</description>
    <arm_group_label>Imatinib</arm_group_label>
    <other_name>Glivec/Gleevec</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Diagnosis of chronic myeloid leukemia associated with BCR-ABL quantifiable by RQ-PCR
        Documented CCyR by bone marrow or BCR-ABL&lt;1% IS in the past 12 months Persistent disease
        demonstrated by two PCR positive tests 3 months apart both during the past 6 months.

        Treatment with imatinib for at least 2 years with 400 mg or 600 mg and a stable dose No
        other current or planned anti-leukemia therapies

        Exclusion Criteria:

        Patient has evidence of rising PCR (a confirmed &gt;1 log increase in previous 6 months)
        Patient has received another investigational agent within last 6 months or tyrosine kinase
        inhibitors (TKIs) other than imatinib Prior allogeneic stem cell transplantation

        Impaired cardiac function including any one of the following:

        Inability to monitor the QT interval on electrocardiogram (ECG) Long QT syndrome or a known
        family history of long QT syndrome. Clinically significant resting brachycardia (&lt;50 beats
        per minute) QTc &gt; 450 msec on baseline ECG (using the QTcF formula). If QTcF &gt;450 msec and
        electrolytes are not within normal ranges, electrolytes should be corrected and then the
        patient re-screened for QTc Myocardial infarction within 12 months prior to starting study
        Other clinically significant uncontrolled heart disease (e.g. unstable angina, congestive
        heart failure or uncontrolled hypertension) History of or presence of clinically
        significant ventricular or atrial tachyarrhythmias Administration of cytokine therapy (e.g.
        G-CSF, GM-CSF or SCF) within 4 weeks prior to study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1221ADH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Prahran</city>
        <state>Victoria</state>
        <zip>3181</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Belo Horizonte</city>
        <state>MG</state>
        <zip>30130-100</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Curitiba</city>
        <state>PR</state>
        <zip>80060-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>21941-913</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Campinas</city>
        <state>SP</state>
        <zip>13083-970</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8H 4J9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1J 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lyon cedex 04</city>
        <zip>69317</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Malaga</city>
        <state>Andalucia</state>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>France</country>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>Mexico</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2008</study_first_submitted>
  <study_first_submitted_qc>September 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2008</study_first_posted>
  <results_first_submitted>July 1, 2016</results_first_submitted>
  <results_first_submitted_qc>July 1, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 16, 2016</results_first_posted>
  <last_update_submitted>October 4, 2016</last_update_submitted>
  <last_update_submitted_qc>October 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MYELOGENOUS</keyword>
  <keyword>LEUKEMIA</keyword>
  <keyword>Chronic Phase</keyword>
  <keyword>CML</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants were randomized 1:1. Participants in the imatinib arm were permitted to cross-over to nilotinib after 2 years on study if complete molecular response (CMR) was not achieved, or at any time during the study if participants experienced treatment failure, had confirmed loss of major molecular response (MMR) or had confirmed loss of CMR.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Nilotinib</title>
          <description>Participants received Nilotinib 400 mg orally twice daily (bid) for 48 months.</description>
        </group>
        <group group_id="P2">
          <title>Imatinib</title>
          <description>Participants received Imatinib 400 mg or 600 mg once daily (qd) (based on the participant's dose prior to randomization) for 48 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="104"/>
                <participants group_id="P2" count="103"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Cross-over to Nilotinib</title>
              <participants_list>
                <participants group_id="P1" count="0">Not applicable: cross-over occurred from imatinib to nilotinib only.</participants>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Set</title>
              <participants_list>
                <participants group_id="P1" count="101"/>
                <participants group_id="P2" count="103"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="77"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with protocol treatment</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant diagnosed with AML</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant not eligible to cross-over</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participants transferred to AMN107A2408</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Treatment failure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nilotinib</title>
          <description>Participants received Nilotinib 400 mg orally twice daily (bid) for 48 months.</description>
        </group>
        <group group_id="B2">
          <title>Imatinib</title>
          <description>Participants received Imatinib 400 mg or 600 mg once daily (qd) (based on the participant's dose prior to randomization) for 48 months.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="104"/>
            <count group_id="B2" value="103"/>
            <count group_id="B3" value="207"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.3" spread="13.26"/>
                    <measurement group_id="B2" value="49.9" spread="13.07"/>
                    <measurement group_id="B3" value="49.1" spread="13.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Confirmed Best Cumulative Complete Molecular Response (CMR)</title>
        <description>The rate of confirmed best cumulative CMR was defined as the number of participants who had confirmed CMR during the first 12 months of treatment after the randomization date. Participants who achieved confirmed best cumulative CMR during the first 12 months were considered responders. Participants who dropped out early or who did not provide sufficient data for any reason were considered to be non-responders. The definition of CMR is undetectable BCR-ABL (fusion gene formed between bcr gene from chromosome 22 and abl gene from chromosome 9) where BCR-ABL ratio in % international scale (IS) ≤ 0.00001 by real-time quantitative polymerase chain reaction (RQ-PCR) where there was no detectable BCR-ABL and 1) the test had a sensitivity of at least 4.5 logs below the standardized baseline; 2) RQ-PCR negativity was confirmed on the next RQ-PCR sample (usually 3 months later); and 3) the date of confirmed CMR was the date of the first of two negative results with sensitivity &gt;4.5 logs.</description>
        <time_frame>12 months</time_frame>
        <population>The intent-to-treat analysis set, which included all randomized participants, was analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Nilotinib</title>
            <description>Participants received Nilotinib 400 mg orally twice daily (bid) for 48 months.</description>
          </group>
          <group group_id="O2">
            <title>Imatinib</title>
            <description>Participants received Imatinib 400 mg or 600 mg once daily (qd) (based on the participant's dose prior to randomization) for 48 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Confirmed Best Cumulative Complete Molecular Response (CMR)</title>
          <description>The rate of confirmed best cumulative CMR was defined as the number of participants who had confirmed CMR during the first 12 months of treatment after the randomization date. Participants who achieved confirmed best cumulative CMR during the first 12 months were considered responders. Participants who dropped out early or who did not provide sufficient data for any reason were considered to be non-responders. The definition of CMR is undetectable BCR-ABL (fusion gene formed between bcr gene from chromosome 22 and abl gene from chromosome 9) where BCR-ABL ratio in % international scale (IS) ≤ 0.00001 by real-time quantitative polymerase chain reaction (RQ-PCR) where there was no detectable BCR-ABL and 1) the test had a sensitivity of at least 4.5 logs below the standardized baseline; 2) RQ-PCR negativity was confirmed on the next RQ-PCR sample (usually 3 months later); and 3) the date of confirmed CMR was the date of the first of two negative results with sensitivity &gt;4.5 logs.</description>
          <population>The intent-to-treat analysis set, which included all randomized participants, was analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Responders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-responders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1083</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.096</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.766</ci_lower_limit>
            <ci_upper_limit>5.738</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Confirmed Best Cumulative CMR</title>
        <description>The rate of confirmed best cumulative CMR was defined as the number of participants who had confirmed CMR during the 24, 36 and 48 months post treatment after the randomization date. Participants who achieved confirmed best cumulative CMR during the first 12 months were considered responders. Participants who dropped out early or who did not provide sufficient data for any reason were considered to be non-responders. The definition of CMR is undetectable BCR-ABL (fusion gene formed between bcr gene from chromosome 22 and abl gene from chromosome 9) where BCR-ABL ratio in % international scale (IS) ≤ 0.00001 by RQ-PCR where there was no detectable BCR-ABL and 1) the test had a sensitivity of at least 4.5 logs below the standardized baseline; 2) RQ-PCR negativity was confirmed on the next RQ-PCR sample (usually 3 months later); and 3) the date of confirmed CMR was the date of the first of two negative results with sensitivity &gt;4.5 logs.</description>
        <time_frame>24 months, 36 month, 48 months</time_frame>
        <population>The intent-to-treat analysis set, which included all randomized participants, was analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Nilotinib</title>
            <description>Participants received Nilotinib 400 mg orally twice daily (bid) for 48 months.</description>
          </group>
          <group group_id="O2">
            <title>Imatinib</title>
            <description>Participants received Imatinib 400 mg or 600 mg once daily (qd) (based on the participant's dose prior to randomization) for 48 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Confirmed Best Cumulative CMR</title>
          <description>The rate of confirmed best cumulative CMR was defined as the number of participants who had confirmed CMR during the 24, 36 and 48 months post treatment after the randomization date. Participants who achieved confirmed best cumulative CMR during the first 12 months were considered responders. Participants who dropped out early or who did not provide sufficient data for any reason were considered to be non-responders. The definition of CMR is undetectable BCR-ABL (fusion gene formed between bcr gene from chromosome 22 and abl gene from chromosome 9) where BCR-ABL ratio in % international scale (IS) ≤ 0.00001 by RQ-PCR where there was no detectable BCR-ABL and 1) the test had a sensitivity of at least 4.5 logs below the standardized baseline; 2) RQ-PCR negativity was confirmed on the next RQ-PCR sample (usually 3 months later); and 3) the date of confirmed CMR was the date of the first of two negative results with sensitivity &gt;4.5 logs.</description>
          <population>The intent-to-treat analysis set, which included all randomized participants, was analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24 months, Responders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 months, Non-responders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 months, Responders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 months, Non-responders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 months, Responders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 months, Non-responders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Cross-over Participants With CMR</title>
        <description>The definition of CMR is undetectable BCR-ABL (fusion gene formed between bcr gene from chromosome 22 and abl gene from chromosome 9) where BCR-ABL ratio in % international scale (IS) ≤ 0.00001 by RQ-PCR where there was no detectable BCR-ABL and 1) the test had a sensitivity of at least 4.5 logs below the standardized baseline; 2) RQ-PCR negativity was confirmed on the next RQ-PCR sample (usually 3 months later); and 3) the date of confirmed CMR was the date of the first of two negative results with sensitivity &gt;4.5 logs.</description>
        <time_frame>24 months, 36 months, 48 months</time_frame>
        <population>Participants from the Imatinib treatment group who crossed over to the Nilotinib treatment group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Nilotinib</title>
            <description>Participants received Nilotinib 400 mg orally twice daily (bid) for 48 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Cross-over Participants With CMR</title>
          <description>The definition of CMR is undetectable BCR-ABL (fusion gene formed between bcr gene from chromosome 22 and abl gene from chromosome 9) where BCR-ABL ratio in % international scale (IS) ≤ 0.00001 by RQ-PCR where there was no detectable BCR-ABL and 1) the test had a sensitivity of at least 4.5 logs below the standardized baseline; 2) RQ-PCR negativity was confirmed on the next RQ-PCR sample (usually 3 months later); and 3) the date of confirmed CMR was the date of the first of two negative results with sensitivity &gt;4.5 logs.</description>
          <population>Participants from the Imatinib treatment group who crossed over to the Nilotinib treatment group were analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival (PFS)</title>
        <description>PFS was defined as the time from the date of randomization to the date of the earliest documented progression-defining event as follows: transformation to blast crisis or accelerated phase disease, or death from any cause.</description>
        <time_frame>48 months</time_frame>
        <population>24 months, Non-responders</population>
        <group_list>
          <group group_id="O1">
            <title>Nilotinib</title>
            <description>Participants received Nilotinib 400 mg orally twice daily (bid) for 48 months.</description>
          </group>
          <group group_id="O2">
            <title>Imatinib</title>
            <description>Participants received Imatinib 400 mg or 600 mg once daily (qd) (based on the participant's dose prior to randomization) for 48 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS)</title>
          <description>PFS was defined as the time from the date of randomization to the date of the earliest documented progression-defining event as follows: transformation to blast crisis or accelerated phase disease, or death from any cause.</description>
          <population>24 months, Non-responders</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The median and 95% confidence interval (CI) could not be calculated because there were too few events.</measurement>
                    <measurement group_id="O2" value="NA">The median and 95% CI could not be calculated because there were too few events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event-free Survival</title>
        <description>Event-free survival was defined as the time from the date of randomization to the date of first occurrence of any of the following events on study treatment: loss of complete hematological response, confirmed loss of complete cytogenetic response (CCyR), confirmed loss of major molecular response (MMR), death from any cause during treatment, progression to the accelerated phase or blast crisis of chronic myelogenous leukemia (CML) per European Leukemia Network (ELN) criteria, whichever was earliest.</description>
        <time_frame>48 months</time_frame>
        <population>The intent-to-treat analysis set, which included all randomized participants, was analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Nilotinib</title>
            <description>Participants received Nilotinib 400 mg orally twice daily (bid) for 48 months.</description>
          </group>
          <group group_id="O2">
            <title>Imatinib</title>
            <description>Participants received Imatinib 400 mg or 600 mg once daily (qd) (based on the participant's dose prior to randomization) for 48 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Event-free Survival</title>
          <description>Event-free survival was defined as the time from the date of randomization to the date of first occurrence of any of the following events on study treatment: loss of complete hematological response, confirmed loss of complete cytogenetic response (CCyR), confirmed loss of major molecular response (MMR), death from any cause during treatment, progression to the accelerated phase or blast crisis of chronic myelogenous leukemia (CML) per European Leukemia Network (ELN) criteria, whichever was earliest.</description>
          <population>The intent-to-treat analysis set, which included all randomized participants, was analyzed.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The median and 95% CI could not be calculated because there were too few events.</measurement>
                    <measurement group_id="O2" value="NA">The median and 95% CI could not be calculated because there were too few events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Overall survival was defined as the time from the date of randomization to the date of death due to any cause at any time during the study, including the follow-up period after discontinuation of treatment.</description>
        <time_frame>48 months</time_frame>
        <population>The intent-to-treat analysis set, which included all randomized participants, was analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Nilotinib</title>
            <description>Participants received Nilotinib 400 mg orally twice daily (bid) for 48 months.</description>
          </group>
          <group group_id="O2">
            <title>Imatinib</title>
            <description>Participants received Imatinib 400 mg or 600 mg once daily (qd) (based on the participant's dose prior to randomization) for 48 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall survival was defined as the time from the date of randomization to the date of death due to any cause at any time during the study, including the follow-up period after discontinuation of treatment.</description>
          <population>The intent-to-treat analysis set, which included all randomized participants, was analyzed.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The median and 95% CI could not be calculated because there were too few events.</measurement>
                    <measurement group_id="O2" value="NA">The median and 95% CI could not be calculated because there were too few events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Nilotinib</title>
          <description>Nilotinib</description>
        </group>
        <group group_id="E2">
          <title>Imatinib</title>
          <description>Imatinib</description>
        </group>
        <group group_id="E3">
          <title>Imatinib Subset That Crossed Over to Nilotinib</title>
          <description>Imatinib subset that crossed over to nilotinib</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE CORONARY SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>ATRIAL FLUTTER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>CARDIOPULMONARY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>LEFT VENTRICULAR DYSFUNCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>PERICARDITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>ANAL FISSURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>CROHN'S DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>INFLUENZA LIKE ILLNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>ERYSIPELAS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>INFECTED SKIN ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>LOWER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>LUNG INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>OSTEOMYELITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ANKLE FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>BACK INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>DRUG ADMINISTRATION ERROR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>LIGAMENT RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>MUSCLE INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>INTERVERTEBRAL DISC PROTRUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>SPINAL COLUMN STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>ACUTE MYELOID LEUKAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>MALIGNANT MELANOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>METASTASES TO PERITONEUM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>NON-SMALL CELL LUNG CANCER METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>RENAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CEREBRAL ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>CEREBRAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>EMBOLIC STROKE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>BLADDER DILATATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>URINARY RETENTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>LUNG DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ARTERIAL OCCLUSIVE DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>PERIPHERAL VASCULAR DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>VASCULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="99" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CONJUNCTIVAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>INFLUENZA LIKE ILLNESS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERBILIRUBINAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>FOLLICULITIS</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>AMYLASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>ASPARTATE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>BILIRUBIN CONJUGATED INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>BLOOD BILIRUBIN INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>BLOOD CHOLESTEROL INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>BLOOD CREATINE PHOSPHOKINASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>BLOOD CREATININE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>GAMMA-GLUTAMYLTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>GLOBULINS DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>HIGH DENSITY LIPOPROTEIN DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>LIPASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>LOW DENSITY LIPOPROTEIN INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>HYPERCHOLESTEROLAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>HYPERTRIGLYCERIDAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>HYPOPHOSPHATAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>DRY SKIN</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>RASH FOLLICULAR</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

